Non-interventional, retrospective & anonymized data base study on breast tumors for markers predictive of risk of recurrence

JOINT EVENT:25^th World Congress on CANCER SCIENCE AND THERAPY & 10^th World Congress on BIOMARKERS & CLINICAL RESEARCH

October 18-20, 2017 Baltimore, USA

Kamuju Suryahari, Immadi Sreevallika

Clinical Trials, India

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

Non-interventional, retrospective & anonymized data base study on breast tumors for markers predictive of risk of recurrence: This is a non-interventional, anonym zed and retrospective research study. It does not involve enrollment of patients/administration of drugs. The study uses left over FEPE tumor blocks remaining after routine diagnosis for the patient is over. IHC/RTPCR based tests will be done on these blocks. Each patient will be de-identified with a unique code, by the hospital. No contact between patient and researcher at any point of time, thus study will have no side effects on the health of the patient. Main aim the study To carry out a non -intervenaial, retrospective & anonymized study on 2000 breast cancer tumors to assess biomarkers for : i) Prediction of risk of cancer recurrence ii) Usefulness of chemo/radio therapy iii) Overall effective cancer treatment planning. Benefits : 1) Patients will avoid excessive therapy/ side effects & enjoy improved quality of life & save resources. 2) Medical oncologists can prescribe most effective therapy and targeted drugs. Cancer and Recurrence: *ASCO report: 1M new cancer cases in India per year. 12 Million Breast cancer survivors in US. In India 2.4M breast cancer cases. *Cancer recurrence is the most feared aspect of cancer as it is responsible for the Morbidity and mortality associated with the disease. *Current means to predict risk of recurrence are limited. Treatment can be planned optimally if recurrence information is available. Mission: To develop novel diagnostic tests for prediction of risk of recurrence for ALL cancers, first focus on breast cancer. Clinical Trials Company Established in Year 2015. Currently the company is working with leading Medical Oncologists in India. Involving the Clinical Trials as well as the Molecular testing and Bio Marker Investigations. Most of the Trials involved in Medical Oncology related areas such as (Breast Cancer, Metastatic Colorectal Cancer, Head & Neck Cancer and other Lymphomas.

Biography :

Mr. Kamaju Suryahari and Ms. Sreevallika Immadi is working with Clinical Trials company for the past 3 years. Both are involved in active participation in running the company. The Basic profile related company is to provide Diagnostic tests in lower cost which help rural Indian Population. The Primary aim of the company is to promote low cost Biomarker Investigations for Rural Indian Population. Where they not able to afford for corporate pricing of the Bio Marker Investigations. Mr. Kamaju Suryahari is having almost 14 years of experience in Oncology Trials and well versed in Solid Tumor Test Based Investigations Related Studies. Ms. Immadi Sreevallika is having almost 2 years experience related to Oncology Therapeutic Area BasedStudies.